Why is Mangalam Drugs falling/rising?

Persistent Downtrend and Underperformance Against Benchmarks

The stock has been on a steep decline over multiple time horizons. Over the past week, Mangalam Drugs has lost 34.16% of its value, while the Sensex gained 0.87%. The one-month performance is even more stark, with the stock plunging 59.56% compared to a 2.03% rise in the benchmark. Year-to-date, the stock has fallen 77.00%, in sharp contrast to the Sensex’s 9.60% gain. Over the last year, the stock’s decline of 78.20% starkly contrasts with the Sensex’s 7.32% appreciation. This underperformance extends to the three- and five-year periods, where Mangalam Drugs has lost over 81% of its value while the Sensex has surged by 35.33% and 91.78% respectively.

Weak Financial Fundamentals Weighing on Investor Confidence

The company’s financial results have been disappointing, with three consecutive quarters of negative earnings. The latest quarterly profit after tax (PAT) stood at a loss of ₹7.35 crores, a dramatic fall of 201.2% compared to the previous four-quarter average. Net sales have also hit a low of ₹49.54 crores, while interest expenses have surged to ₹5.03 crores, indicating rising financial strain. These figures highlight the company’s struggle to generate sustainable profits and manage its debt burden effectively.

The company’s long-term fundamentals remain weak, as evidenced by a high Debt to EBITDA ratio of 5.66 times, signalling limited capacity to service debt. Additionally, the average return on equity (ROE) is a modest 5.83%, reflecting low profitability relative to shareholders’ funds. This combination of high leverage and poor returns undermines investor confidence and contributes to the stock’s persistent decline.

Technical Indicators and Market Sentiment

On 01-Dec, Mangalam Drugs opened with a gap down of 4.99%, trading within a wide intraday range of ₹2.80, touching a high of ₹29.47 and a low of ₹26.67. The weighted average price indicates that most trading volume occurred near the day’s low, suggesting selling pressure. The stock is trading below all key moving averages—5-day, 20-day, 50-day, 100-day, and 200-day—signalling a bearish trend. Investor participation has also diminished, with delivery volumes on 28 Nov falling by 78.78% compared to the five-day average, reflecting waning interest from long-term holders.

Promoter Shareholding and Additional Downside Risks

Adding to the negative sentiment is the high level of promoter share pledging, which currently stands at 34.58%. This represents a 21.35% increase over the last quarter. Elevated pledged shares often exert downward pressure on stock prices, especially in falling markets, as promoters may be forced to liquidate holdings to meet margin calls. This factor exacerbates the stock’s vulnerability and contributes to its ongoing decline.

Long-Term Underperformance and Risk Profile

Mangalam Drugs’ stock has consistently underperformed not only the Sensex but also the broader BSE500 index over the last three years, one year, and three months. The company’s profits have contracted by over 300% in the past year, underscoring the severity of its operational challenges. This poor profitability, combined with high leverage and negative operating margins, renders the stock risky relative to its historical valuation levels. Investors have responded accordingly, reflected in the steep and sustained price decline.

Conclusion

The sharp fall in Mangalam Drugs’ share price on 01-Dec is the culmination of prolonged weak financial performance, deteriorating fundamentals, and negative market sentiment. The company’s inability to generate profits, coupled with rising debt servicing costs and increased promoter share pledging, has eroded investor confidence. Technical indicators confirm a bearish trend, while reduced investor participation signals a lack of buying interest. Until there is a meaningful turnaround in earnings and balance sheet strength, the stock is likely to remain under pressure.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →